drugset / Trial / NCT07185815

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

NCT07185815

Phase 1/2 Recruiting 24 enrolled Mapi Pharma Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine Depot in subjects eligible for treatment with oral Cariprazine.

Timeline

Start
2025-08-01
Primary completion
2026-12-31
Completion
2027-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 3 mg Subcutaneous
Subject Cariprazine Small molecule 22 mg Subcutaneous
Subject Cariprazine Small molecule 44 mg Subcutaneous